Targeting lactate metabolism is emerging as a promising strategy in cancer treatment. Inhibitors of lactate dehydrogenase (LDH), the enzyme responsible for converting pyruvate to lactate, are being explored to disrupt the metabolic flexibility of cancer cells. Additionally, therapies aimed at neutralizing the acidic tumor microenvironment could enhance the efficacy of existing treatments.
